Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters.

07:00 EST 13th February 2020 | BioPortfolio

Summary of "Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters."

Just a few weeks before the first confirmed case of novel coronavirus (COVID-19) was reported in the United States, the US Centers for Disease Control and Prevention (CDC) issued a bold promise to the nation: the agency will use its scientific expertise to bring a new level of preparedness in the United States and global health security against current and growing threats, finally eliminate certain diseases, and bring an end to the devastation of epidemics. The current outbreak of COVID-19 reminds us how urgent this promise is and just how critical it is to continue to sustain and strengthen our nation's public health infrastructure. The unprecedented pace of the public health response to COVID-19 has only been possible because of prior investments in public health preparedness. To accelerate our pace and meet the challenges of current and future health threats, we must advance our world-class data and analytics capabilities; maintain and expand our state-of-the-art public health laboratory capacity; continue building a workforce of trusted, expert, public health professionals; sustain our capacity to rapidly respond to outbreaks at their source; and assure a strong global and domestic preparedness capacity. (. Published online ahead of print February 13, 2020: e1-e2. doi:10.2105/AJPH.2020.305618).


Journal Details

This article was published in the following journal.

Name: American journal of public health
ISSN: 1541-0048
Pages: e1-e2


DeepDyve research library

PubMed Articles [8481 Associated PubMed Articles listed on BioPortfolio]

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?

To provide an overview of the three major deadly coronaviruses and identify areas for improvement of future preparedness plans, as well as provide a critical assessment of the risk factors and actiona...

Coronavirus Disease 2019 (COVID-19): A Perspective from China.

In December 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occurred in Wuhan, Hubei Province, China and spread across China and beyond. On February 12, 202...

COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00 AEDT 15 February 2020).

This is the third epidemiological report for coronavirus disease 2019 (COVID-19), previously known as novel coronavirus (2019-nCoV), from the virus now known as SARS-CoV-2, reported in Australia as at...

Risk for Transportation of 2019 Novel Coronavirus Disease from Wuhan to Other Cities in China.

On January 23, 2020, China quarantined Wuhan to contain 2019 novel coronavirus disease (COVID-19). We estimated the probability of transportation of COVID-19 from Wuhan to 369 other cities in China be...

COVID-19, Australia: Epidemiology Report 2 (Reporting week ending 19:00 AEDT 8 February 2020).

This is the second epidemiological report for coronavirus disease (COVID-19), previously known as novel coronavirus (2019-nCoV), reported in Australia as at 19:00 Australian Eastern Daylight Time [AED...

Clinical Trials [4002 Associated Clinical Trials listed on BioPortfolio]

The Investigation of the Neonates With or With Risk of COVID-19

Since December 2019, there has been an outbreak of novel coronavirus pneumonia in China. As of February 18, 2020, 72,530 cases confirmed with 2019 coronavirus disease(COVID-19) have been r...

Efficacy and Safety of Corticosteroids in COVID-19

There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explor...

Fingolimod in COVID-19

Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane for...

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

The novel identified coronavirus (SARS-CoV-2) in 2019 causes an nationwide outbreak as well as public health crisis in China, and expands globally. Pulmonary edema is one of the most detri...

Humanistic Care in Healthcare Workers in Coronavirus Disease 2019

As of February 17th, 2020, China has 76396 confirmed cases of coronavirus disease 2019 (COVID-19), including 2348 deaths. The impact factors of clinical outcomes among hospitalized patient...

Medical and Biotech [MESH] Definitions

A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It contains hemagglutinin-esterase.

A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It lacks hemagglutinin-esterase.

The type species of BETACORONAVIRUS genus causing gastroenteritis respiratory diseases in mammals. Previously separate species HUMAN CORONAVIRUS OC43; BOVINE CORONAVIRUS; Human enteric coronavirus; Equine coronavirus; and Porcine hemagglutinating encephalomyelitis virus merged into this species on the basis of similar genome nucleotide sequence and genome organization.

A species of CORONAVIRUS causing enteritis in turkeys and pullets.

A species of CORONAVIRUS infecting neonatal calves, presenting as acute diarrhea, and frequently leading to death.

Quick Search

DeepDyve research library

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

Searches Linking to this Article